CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric receptor-engineered T cells offer therapeutic potential against tumors.
• Limitations include inherent T cell toxicities and overcoming tumor microenvironment immunosuppression.

Purpose of the Study:

• To develop a novel synNotch T cell platform for targeted tumor therapy.
• To investigate the role of CXCL10 in mediating anti-tumor effects.

Main Methods:

• Development of a Notch receptor-based synNotch T cell platform.
• Administration of synNotch T cells in a humanized murine tumor model.
• Analysis of immune cell infiltration and cytokine levels (CXCL10, IFN-γ) in tumor sites and serum.

Main Results:

• SynNotch T cells significantly inhibited tumor growth in vivo.
• Increased infiltration of CD3+ T cells and elevated CXCL10 and IFN-γ levels were observed in tumors.
• CXCL10 was identified as essential and sufficient for the anti-tumor effect induced by synNotch T cells.

Conclusions:

• The synNotch T cell platform effectively targets tumors and enhances anti-tumor immunity.
• CXCL10 plays a critical role in mediating the therapeutic efficacy of these engineered T cells.
• This approach provides a foundation for clinical applications of CXCL10-encoding synNotch T cells.